During the past decade, Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0 conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0" #1 collaborator was "Eisai Inc." with 3 trials as a collaborator, "European Network for Gynaecological Oncological Trial Groups" with 2 trials as a collaborator, "Gynecologic Oncology Group" with 2 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0" are "Carcinoma, Renal Cell" (2 trials), "Advanced Solid Neoplasms" (1 trials), "Advanced Solid Tumors" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials) and "Carcinoma, Ovarian Epithelial" (1 trials). Many other conditions were trialed in "Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0" in a lesser frequency.

Most popular intervention types in "Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0" are "Drug" (11 trials), "Biological" (8 trials), "Radiation" (3 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (10 trials), "Cisplatin" (4 trials), "Belzutifan" (3 trials), "Lenvatinib" (3 trials) and "Paclitaxel" (3 trials). Other intervention names were less common.

The vast majority of trials in "Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0" are 9 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".